Effect of MK0524A on Cholesterol Levels (0524A-048)

Summary

The primary objective of the study is to assess the effects of MK0524A in reducing cholesterol levels in an Asian population.

Timeline

Start

2007-04

Primary completion

2008-03

Completion

2008-03

Outcome

Met primary endpoint

registry MK0524A 2 g vs Placebo; p <0.001; Mean Difference (Final Values) -14.7 (95% CI -18.6 to -10.9); ANOVA NCT00536510 ↗

Publications

• Results Kush D, Kim HS, Hu DY, Liu J, Sirah W, Sapre A, McCrary Sisk C, Paolini JF, Maccubbin D. Lipid-modifying efficacy of extended release niacin/laropiprant in Asian patients with primary hypercholesterolemia or mixed hyperlipidemia. J Clin Lipidol. 2009 May-Jun;3(3):179-86. doi: 10.1016/j.jacl.2009.04.048. Epub 2009 May 3.

Drugs

Indications